Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Managing type 2 diabetes is complex and necessitates careful consideration of patient factors such as engagement in self-care, comorbidities and costs. Since type 2 diabetes is a progressive disease, many patients will require injectable agents, usually insulin. Recent ADA-EASD guidelines recommend glucagon-like peptide 1 receptor agonists (GLP-1 RAs) as first injectable therapy in most cases. The basis for this recommendation is the similar glycemic efficacy of GLP-1 RAs and insulin, but with GLP-1 RAs promoting weight loss instead of weight gain, at lower hypoglycemia risk, and with cardiovascular benefits in patients with pre-existing cardiovascular disease. GLP-1 RAs also reduce burden of glucose self-monitoring. However, tolerability and costs are important considerations, and notably, rates of drug discontinuation are often higher for GLP-1 RAs than basal insulin. To minimize risk of gastrointestinal symptoms patients should be started on lowest doses of GLP-1 RAs and up-titrated slowly. Overall healthcare costs may be lower with GLP-1 RAs compared to insulin. Though patient-level costs may still be prohibitive, GLP-1 RAs can replace 50–80 units of insulin daily and reduce costs associated with glucose self-monitoring. Decisions regarding initiating injectable therapy should be individualized. This review provides a framework to guide decision-making in the real-world setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636 · cited 1×
“While insulins are safe to use in patients with pre-existing CVD they lack evidence for cardiovascular benefit [32,33]; thus GLP-1 RAs should be preferred in this scenario [3].”
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“The longacting GLP-1 RAs exhibit greater impact on fasting glucose levels [11,12].”
BackgroundSelf-citationon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784 · cited 2×
“[37] Likewise, adherence is better for insulin pens than insulin administered by vial and syringe.[36, 38] Hence, when comparing ease of use between medication classes, differences will be wider between GLP-1 RAs and insulin administered by vial and syringe, versus GLP-1 RAs and insulin delivered via pen; the latter c…”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 10×
“As discussed by Rizzo et al. in this issue, except for lixisenatide the GLP-1 RAs have demonstrated broad-based benefits on atherosclerotic cardiovascular disease outcomes and/or mortality in patients with preexisting CVD.”
BackgroundInfluentialAhmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574 · cited 1×
“While insulins are safe to use in patients with pre-existing CVD they lack evidence for cardiovascular benefit [32,33]; thus GLP-1 RAs should be preferred in this scenario [3].”
BackgroundSelf-citationFilippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Early Worsening of Diabetic Retinopathy in the Diabetes Control and Complications Trial
(1998) · Archives of Ophthalmology · doi:10.1001/archopht.116.7.874 · Cited by 509
Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407 · cited 1×
“Efficacy of glucose-lowering agents relies heavily on adherence, which is inversely related to number of daily injections.[39] With the exception of twice-daily exenatide, all other GLP-1 RAs allow for the same or lower number of injections compared to basal insulin (typically once daily).”
BackgroundGiorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260 · cited 1×
“Concurrent initiation of basal insulin and GLP-1 RA can offset weight gain due to insulin, and combination formulations have even demonstrated reductions in weight [20,21].”
BackgroundBuse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259 · cited 3×
“In the Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes (DUAL) II trial [26], 413 patients on basal insulin and metformin (±sulfonylurea or glinides) were randomized to once-daily insulin degludec/liraglutide+metformin or once-daily degludec+metformin in a blinded fashion.”
BackgroundSelf-citationInsulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243 · cited 1×
“However, evidence suggests that GLP-1 RAs do increase risk of cholelithiasis [48,50,51], though this does not translate to increase in gallstone-associated acute pancreatitis.”
BackgroundNauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Sikirica, M., Martin, A., Wood, R., Leith, A., Piercy, J., & Higgins, V. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s141235 · Cited by 223 · cited 2×
“Real-world persistence to GLP-1 RAs varies by study, but is in the range of 47% to 80%, and tends to be higher for dulaglutide than for exenatide or liraglutide [4,42].”
BackgroundLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“Concurrent initiation of basal insulin and GLP-1 RA can offset weight gain due to insulin, and combination formulations have even demonstrated reductions in weight [20,21].”
BackgroundSelf-citationStorgaard, H., Cold, F., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12885 · Cited by 155 · cited 1×
“However, evidence suggests that GLP-1 RAs do increase risk of cholelithiasis [48,50,51], though this does not translate to increase in gallstone-associated acute pancreatitis.”
BackgroundCarls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153 · cited 1×
“Lack of adherence accounted for 75% of this discrepancy [16].”
BackgroundInsulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113 · cited 3×
“[7, 22] In contrast, insulin leads to weight gain of 3 to 9 kg within the first year of initiation.[19] While obese patients are traditionally considered at highest risk of further weight gain and its consequences,[19] real-world data suggests that patients with normal body mass index (BMI) experience more relative we…”
BackgroundInfluentialGlucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
Self-citationCastellana, M., Cignarelli, A., Brescia, F., Laviola, L., & Giorgino, F. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3082 · Cited by 84 · cited 1×
“When comparing patient-level costs, it is important to consider that GLP-1 RAs can replace 50–80 units of insulin with similar glycemic efficacy [10,55].”
BackgroundOnce-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir
Davies, M., Heller, S., Sreenan, S., Sapin, H., Adetunji, O., Tahbaz, A., & Vora, J. (2013) · Diabetes Care · doi:10.2337/dc12-1333 · Cited by 83 · cited 1×
“[71] Met ± SU 26 weeks Exenatide 2 mg weekly −1.”
D'Alessio, D., Häring, H. ‐., Charbonnel, B., de Pablos‐Velasco, P., Candelas, C., Dain, M. ‐., Vincent, M., Pilorget, V., Yki‐Järvinen, H., & on behalf of the EAGLE Investigators (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12406 · Cited by 56 · cited 1×
“Of note, even in the context RCTs comparing once-daily GLP-1 RA (liraglutide) to once-daily basal insulin, discontinuation rates for GLP-1 RA were higher [17].”
BackgroundMaiorino, M. I., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Esposito, K., & Giugliano, D. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13343 · Cited by 52
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40 · cited 14×
“Glycemic efficacy versus effectiveness While the efficacy of GLP-1 RA therapy and insulin appear similar in randomized controlled trials (RCTs), it is worthwhile noting that patients enrolled in RCTs are highly selected individuals who are likelymoremotivated, adherent, and supported, thus are not reflective of popula…”
BackgroundInfluentialIs there a justification for classifying GLP-1 receptor agonists as basal and prandial?
Miñambres, I., & Pérez, A. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0204-6 · Cited by 39 · cited 1×
“The long-acting GLP-1 RAs exhibit greater impact on fasting glucose levels.[11, 12] Therefore, in addition to exploring GLP-1 RAs as alternatives to basal insulin, they have been examined in comparison to prandial and premixed insulins (Table 2), both in the presence and absence of basal insulin therapy.”
BackgroundIs insulin the most effective injectable antihyperglycaemic therapy?
Buse, J. B., Peters, A., Russell‐Jones, D., Furber, S., Donsmark, M., Han, J., MacConell, L., Maggs, D., & Diamant, M. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12402 · Cited by 32
Self-citationDurden, E., Liang, M., Fowler, R., Panton, U. H., & Mocevic, E. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.18429 · Cited by 30 · cited 1×
“[18] found that patients were more likely to adhere to GLP1 RA therapy over an 18 month period if they experienced an HbA1c reduction of N1% (OR 1.”
BackgroundYu, M., Mody, R., Landó, L. F., Shui, A., Kallenbach, L., Slipski, L., & de Oliveira, C. P. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.11.001 · Cited by 15 · cited 2×
“While obese patients are traditionally considered at highest risk of further weight gain and its consequences [19], real-world data suggests that patients with normal body mass index (BMI) experience more relative weight gain when starting insulin compared to obese patients [23].”
Background
Cited by
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
GLP-1 agonists for weight loss: pharmacology and clinical implications.
Moore, P. W., Malone, K., VanValkenburg, D., Rando, L. L., Williams, B. C., Matejowsky, H. G., Ahmadzadeh, S., Shekoohi, S., Cornett, E. M., & Kaye, A. D. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02394-w · Cited by 86
Yang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01211-4 · Cited by 51
“However, the common gastrointestinal symptoms and higher drug acquisition costs of GLP-1RAs have hindered their widespread and continuous use in real-world settings [2, 5].”
BackgroundInfluentialPalanca, A., Ampudia-Blasco, F. J., Calderón, J. M., Sauri, I., Martinez-Hervás, S., Trillo, J. L., Redón, J., & Real, J. T. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01382-9 · Cited by 48
Metadata
- Authors
- Alexopoulos, A.-S., & Buse, J. B.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 98
- Pages
- 104-111
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2954613645
- Cited by
- 24
- References
- 35
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.